The online version of this article (doi:10.1186/1477-7819-10-110) contains supplementary material, which is available to authorized users.
The authors have no competing interests to declare.
MK participated in conception of the study, data collection and analysis, and drafted the manuscript. RC participated in conception of the study, data collection and analysis, and helped draft the manuscript. DA participated in conception of the study. EM participated in conception of the study, design and coordination, data analysis, and helped draft the manuscript. All authors read and approved the final manuscript.
In patients with locally advanced or recurrent pelvic malignancies, total pelvic exenteration (TPE) may be necessary for curative treatment. Despite improvements in mortality rates since TPE was first described, morbidity rates remain high due to the extensive resection and the aggressiveness of these tumors. We have studied the outcomes of TPE surgery performed at our institution.
Fifty-three patients with various pelvic pathologies underwent TPE between 2004 and 2010. Patients were divided into two groups based on pathology: colorectal (n = 36) versus non-colorectal (n = 17) malignancies. Demographics, operative reports, pathology reports, periprocedural events, and outcomes were analyzed. Comparison of the two groups was performed using student’s t-test and Fisher’s exact test. Survival curves were constructed using the Kaplan–Meier method and compared using the log rank test.
The colorectal and non-colorectal groups were similar in demographics, operative times, length of stay, estimated blood loss, and rates of preoperative and intraoperative radiation use. Chemotherapy use was increased in the colorectal group compared with the non-colorectal group (55.6% vs. 23.5%, P = 0.04). Complication rates were similar: 86% in the colorectal group and 76% in the non-colorectal group. In the colorectal group, 27.8% of patients developed perineal abscesses, whereas no patients developed these complications in the non-colorectal group (P = 0.02). No survival difference was seen in primary versus recurrent colorectal tumors; however, within the colorectal group there was a survival advantage when comparing R0 resection to R1 and R2 resection combined. Median survival rates were 27.3 months for R0 resection and 10.7 months for R1 and R2 resection combined. The median survival was 21.4 months for the colorectal group and 6.9 months for the non-colorectal group (P = 0.002).
Patients undergoing TPE for colorectal tumors have improved survival when compared with patients undergoing exenteration for pelvic malignancies of other origins. Within the colorectal group, the extent of resection demonstrated a significant survival benefit of an R0 resection compared with R1 and R2 resections. Despite TPE carrying a high morbidity rate, mortality rates have improved and careful patient selection can optimize outcomes.
Brunschwig A: Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer. 1948, 1: 177-283. 10.1002/1097-0142(194807)1:2<177::AID-CNCR2820010203>3.0.CO;2-A. CrossRefPubMed
Bricker EM: Bladder substitution after pelvic evisceration. Surg Clin North Am. 1950, 30: 1511-1521. PubMed
Carter MF, Dalton DP, Garnett JE: Simultaneous diversion of the urinary and fecal streams utilizing a single abdominal stoma: the double-barreled wet colostomy. J Urol. 1989, 141: 1189-1191. PubMed
Lopez MJ, Kraybill WG, Downey RS, Johnston WD, Bricker EM: Exenterative surgery for locally advanced rectosigmoid cancers. Is it worthwhile?. Surgery. 1987, 102: 644-651. PubMed
Falk RE, Moffat FL, Makowka L, Konn G, Bulbul MA, Rotstein LE, Bruce AW: Pelvic exenteration for advanced primary and recurrent adenocarcinoma. Can J Surg. 1985, 28: 539-541. PubMed
Eckhauser FE, Lindenauer SM, Morley GW: Pelvic exenteration for advanced rectal carcinoma. Am J Surg. 1979, 138: 412-414. PubMed
Ike H, Shimada H, Ohki S, Yamaguchi S, Ichikawa Y, Fujii S: Outcome of total pelvic exenteration for locally recurrent rectal cancer. Hepatogastroenterology. 2003, 50: 700-703. PubMed
Lewis JJ, Benedetti F: Adjuvant therapy for soft tissue sarcomas. Surg Oncol Clin North Am. 1997, 6: 847-862.
Lopez MJ: Exenterative pelvic surgery. Surg Clin North Am. 1994, 3: 197-418.
Morley GW, Hopkins MP, Lindenauer SM, Roberts JA: Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol. 1989, 74: 934-943. PubMed
Kraybill WG, Lopez MJ, Bricker EM: Total pelvic exenteration as a therapeutic option in advanced malignant disease of the pelvis. Surg Gynecol Obstet. 1988, 166: 259-263. PubMed
Yeung RS, Moffat FL, Falk RE: Pelvic exenteration for recurrent and extensive primary colorectal adenocarcinoma. Cancer. 1993, 72: 1843-1858.
- Retrospective review of pelvic malignancies undergoing total pelvic exenteration
Maureen P Kuhrt
Ravi J Chokshi
Edward W Martin Jr
- BioMed Central
Neu im Fachgebiet Chirurgie
Mail Icon II